Literature DB >> 102631

In vitro activity of HR 756, a new cephalosporin compound.

P M Shah, G Troche, W Stille.   

Abstract

The in vitro activity of HR 756, a new cephalosporin, has been determined against recent clinical isolates and compared with that of other beta-lactam antibiotics. The geometric means of the minimum inhibitory concentrations (MIC) for different isolates of Escherichia coli (100 isolates), Klebsiella pneumoniae (84), Pseudomonas aeruginosa (121), Proteus mirabilis (52), indole-positive Proteus species (9), Salmonella species (19), Staphylococcus aureus penicillin-sensitive (29) and penicillin-resistant (39) were: 0.095, 0.124, 11.1, 0.095, 0.0107, 0.078, 1 and 0.95 mcg/ml, respectively. Its activity was affected by rise in inoculum against S. aureus and P. aeruginosa but not against K. pneumoniae and E. coli. Bactericidal activity was determined by membrane filtration method. HR 756 was found to be bactericidal to E. coli, K. pneumoniae, P. aeruginosa and Proteus species. Although the MICs of the tested S. aureus strains were 1 mcg/ml, 5 mcg/ml of HR 756 failed to kill 99% of the inoculum within 24 hours.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 102631     DOI: 10.7164/antibiotics.31.1170

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

1.  Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

Authors:  W H Hall; B J Opfer; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

2.  Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.

Authors:  P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

3.  In vitro antimicrobial activity of cefotaxime, a new cephalosporin.

Authors:  S Masuyoshi; S Arai; M Miyamoto; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

4.  Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

5.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

6.  The in vitro activity of beta-lactam antibiotics against gentamicin and/or carbenicillin-resistant Pseudomonas aeruginosa strains.

Authors:  M L Aisa; M Omenaca; C Bergua; J B Garcia-Moya
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 7.  Fluoroquinolones in the treatment of typhoid fever and the carrier state.

Authors:  I Zavala Trujillo; C Quiroz; M A Gutierrez; J Arias; M Renteria
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

8.  Cefotaxime lavage in children undergoing appendicectomy.

Authors:  T A McAllister; A H Fyfe; D G Young; P A Raine
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 9.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

10.  Antimicrobial activity of cefmenoxime (SCE-1365).

Authors:  J M Stamm; R L Girolami; N L Shipkowitz; R R Bower
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.